Solving the $5.3B Patient Recruitment Problem

Author: Mark Wade, Global Practice Leader, TransPerfect Life Sciences

With the patient recruitment market forecasted to reach $5.3 billion by 2030, sponsors can't afford to treat enrollment as an afterthought. Reduce clinical trial delays and regrettable spend with our proven patient recruitment strategies.

patient-recruitment

Challenges in Patient Recruitment

Participant recruitment is constrained by several structural and behavioral bottlenecks that contribute to study delays, including:

  • Icon Analytics 2

Most patients don't know trials exist

88% of participants never discuss their research experience, and 26% of people don't know where trials are conducted.

  • Icon Global Contract

Thousands of trials compete for the same limited participant populations.

Over 60,000 trials are recruiting or have not yet started in the U.S. alone.

  • Icon Progress Bar

One rejection discourages further participation

65% of those who don't qualify for a study don't search for another.

  • Icon QA

Randomization processes and screening introduce high failure rates.

For every 1,000 patients, assuming they don’t have a rare disease, only 10% will actually be randomized.

Why don’t more participants enroll?

61 %

Increase in eligibility criteria

The total number of eligibility criteria for an average Phase III protocol has jumped from 31 to 50 from 2002 to 2012. Source: National Institutes of Health

57 %

Fear side effects

20 %

Fear risks to overall health

13 %

Fear receiving placebo

Planning an AI Strategy

What Works

Successful recruitment programs apply a structured, multi-layered approach rather than relying on a single channel or tactic:

  • Address patient recruitment early, before site activation, rather than treating it as a downstream task
  • Design outreach strategies around real patient behavior and decision patterns
  • Recognize that awareness, eligibility, and enrollment are distinct filtering stages
  • Account for the steep attrition between initial interest and final randomization
  • Treat recruitment as a continuous, measurable process rather than a one-time activity
Learn About Patient Recruitment Strategies ›

How TransPerfect Helps

TransPerfect supports patient recruitment through integrated services that address communication, localization, and operational scale across global trials.

  1. Patient-facing content creation and localization to support multilingual outreach
  2. Translation and adaptation of recruitment and study materials
  3. Support for compliant global communications and documentation
  4. Expertise across therapeutic areas and trial phases
Data Security with AI

Your Patient Recruitment Checklist

So how can we maximize our efforts to recruit patients and keep them for the length of the study?

  • Create meaningful, insightful, and informative web landing pages. They must be readily accessible to potential patients, and written in easy-to-understand prose.

  • Patient facing materials must be culturally acceptable. As we recruit patients globally, we must be mindful of the language, culture, and customs of our target market. Insensitivity can do more harm to a brand than good.

  • Any direct mail needs to be created with brevity in mind. Patients receive significant solicitation mail daily. Study information, if not created succinctly, can be dismissed out of hand.

  • Site and Principal Investigator (PI) literature needs to be able to speak to the clinician in a way that appeals to their clinical needs. This is not to be confused with patient-facing materials. Both need to be addressed with a different mindset.

  • Ensure materials are created by teams that understand the disease state primarily. It is not just about graphics and fuzzy animals. The artwork can come later.

  • Ensure that your provider understands more than simply placing social media advertisements. Ensure that there are metrics for success and a methodology to amend and fine-tune the tactic in real time.

  • Have a plan to transport a subject to a site if they are unable to do so on their own. Remove every barrier to enrollment possible.

  • Ensure that there is a plan to retain the subject once the study has begun. Develop a plan to send encouragement and support throughout the entire lifecycle of the study, for years if necessary.

Ready to Recruit Faster and Retain Longer?

Cut enrollment timelines, cost, and reduce dropout rates with targeted patient solutions.

How did you hear about us?
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Related Resources

From Reactive to Strategic: How AI Is Transforming Medical Information Contact Centers

Blog

Introduction For decades, Medical Information (MI) has been an essential function within pharma, but largely a reactive one. This is especially true in medical information contact centers, which serve as the first line of support for HCPs and patients. When someone has a question about a product, they reach out, receive an answer, and the interaction is considered complete. But was it ever this simple? And what does that model look like in a digital environment where ...

From Reactive to Strategic: How AI Is Transforming Medical Information Contact Centers
Blog

Five Domains the FDA Wants You to Measure in PROs for Cancer—and Why Translation Affects All of Them

In a recent "LifeSci Talks" episode, TransPerfect Global Practice Leader Mark Wade and Signant Health VP and eCOA Scientist Bill Byrom PhD discussed how new FDA guidance is reshaping how sponsors approach patient-reported outcomes (PROs) in cancer clinical trials. PROs...
Webinar

AI in Medical Information: Challenges, Opportunities, and the Path to Compliant Content at Scale

Medical information teams are being asked to do more with less; faster turnaround, broader content demands, and zero tolerance for inaccuracy. AI offers a way forward, but adoption comes with real challenges: how do you validate accuracy, integrate literature review, and build ...
Webinar

Xtalks | Improve Recruitment Outcomes Through More Diverse Clinical Trials

Since the advent of artificial intelligence (AI), medical device manufacturers have been early adopters for product enhancements. Now, manufacturers are evaluating their regulated content and other production processes for suitable applications of AI and automation technology. ...
Blog

Potential Impact of the EU Biotech Act Proposal on Clinical Trial Activities

The European Commission’s proposed Biotech Act introduces changes that could reshape how clinical trials are approved and managed across the EU. While the broader package spans multiple areas of the health ecosystem, proposed updates to the EU Clinical Trial Regulation (EU...
Blog

5 Common eCOA Migration Issues

With so many clinical trials now using COAs on electronic platforms, the practice of “migration” (transferring and adapting COAs for electronic use) has become more common than ever. Without careful implementation, one minor deviation can compound across many languages,...
Checklist

A Checklist for eCOA Solution Deployment: Best Practices and Considerations

Selecting and deploying a new eCOA solution involves many important factors - from determining the capabilities of the Language Service Provider (LSP) to identifying the technology used for each COA migration - and it’s impossible not to worry about missing a key detail in the ...